source
- Neurosterix secures $105M Series B to launch phase 2 schizophrenia trialAddex Therapeutics' spinout Neurosterix announced a $105 million Series B financing to fund its upcoming phase 2 trial of NTX-253 for schizophrenia. The round was led by a syndicate of leading lif…
- Bristol Myers appoints Cristian Massacesi as head of R&D as Robert Plenge exitsBristol Myers Squibb announced a reorganization of its research and development organization, merging the research and development units under a single leader. Cristian Massacesi, currently chief…